Amicus Therapeutics, Inc. · Cranbury, NJ United States (NASDAQ: FOLD)
| 6 Cedar Brook Dr. | Phone: 609-662-2000 |
| Cranbury, NJ | Fax: 609-662-2001 |
| 08512 | |
| United States | 
Map This Company |
Amicus Therapeutics, Inc. Rankings
More Companies in These Related Industries: Company Description
Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological "chaperones" which bind to a patient's own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative diseases including Alzheimer's and Parkinson's.
Amicus Therapeutics, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: FOLD Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 99 |
Executives
48 executives listed for Amicus Therapeutics, Inc.'s Cranbury, NJ location.
| Chairman and CEO | John Crowley | |
|---|---|---|
| President and COO | Matthew Patterson | |
| Principal Financial Officer and Treasurer | Daphne Quimi |